[Dongguang Pharmaceutical's double insulin degluaspart was approved and became the second domestic company of this variety] On October 8, reporters learned from Dongguang Pharmaceutical today that its independently developed double insulin degluaspart was approved for marketing for the treatment of type 2 diabetes in adults. Dongguang Pharmaceutical became the second domestic pharmaceutical company to be approved for this variety, and its domestically approved insulin varieties increased to 7. Relevant people from Dongguang Pharmaceutical told reporters that the approval of Degluaspart dual insulin has completed an important part of the company's layout in the field of fourth-generation insulin, further improved the matrix of diabetes chronic disease products, and strengthened the company's comprehensive competitiveness in the field of hypoglycemic treatment. Xiaocai's Note: The original manufacturer of degluaspart biinsulin is Novo Nordisk. This preparation has the characteristics of long-acting and stable blood sugar control and rapid mealtime blood sugar lowering. According to data from Zhongkang Kaisi, the total sales of this variety in domestic retail and grade hospital channels in 2025 will be approximately 2.5 billion yuan. (Reporter Lu Afeng)